We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Adverse Effects Uncommon Following Colonoscopy

By HospiMedica International staff writers
Posted on 20 Mar 2013
A new study provides further evidence on the safety of both screening and nonscreening colonoscopies in routine practice.

Researchers at the German Cancer Research Center (DKFZ; Heidelberg, Germany) evaluated data of over 30,000 individuals insured with the German statutory health insurance (AOK) who had undergone outpatient colonoscopy between 2001 and 2008; a control group consisted of insured persons who had not had a screening test. More...
The researchers analyzed the incidence of serious adverse events (AEs) such as intestinal wall injuries, intestinal or splenic bleeding, myocardial infarction (MI), stroke, and overall mortality. The period for evaluation included 30 days following the colonoscopy in order to include possible late effects.

The results showed that the incidence of perforation was 0.8 per 1,000 screening and nonscreening colonoscopies. Hospitalizations because of bleeding occurred in 0.5 per 1,000 screening and nonscreening colonoscopies. The incidence of MI, stroke, and other nongastrointestinal AEs was similar in colonoscopy and control groups; no splenic injury was observed. Participants with AEs generally had a higher mean age and comorbidity rate than the overall study population. The study was published in the March 2013 issue of Gastrointestinal Endoscopy.

“For an examination offered to large portions of the population, the question of safety is of central importance. Therefore, it is equally important that physicians and public health experts are very well informed about the risks of complications,” said senior author Prof. Hermann Brenner, MD. “Only then can they profoundly evaluate chances and risks of a colonoscopy with their patients.”

Colon cancer is the second most common cancer in in Germany and the second most common cause of cancer-related death. Approximately 65,000 people are newly diagnosed with colorectal cancer every year and 26,000 people succumbed to the disease in 2010. Since 2002, colonoscopy is part of the national statutory cancer screening program in Germany for all insured persons aged 55 or older, but only one fifth of those eligible actually make use of the screening program. The reasons for this are manifold, including fear of a frightening diagnosis and of a potentially unpleasant examination, which can also lead to complications.

Related Links:

German Cancer Research Center




Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.